Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (31-40 of 184) with videos related to

Pageof 19
Sort By:
BMC Medicine|April 22, 2017
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Jordi Remon, Benjamin Besse, Jean-Charles Soria
Translational Lung Cancer Research|February 11, 2020
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Frontiers in Oncology|April 1, 2022
Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic MalignanciesGiulia Pasello, Jordi Remon, Emanuela Felley-Bosco
Future Oncology (London, England)|May 16, 2020
Combination treatments with immunotherapy in brain metastases patientsClemence Henon, Jordi Remon, Lizza El Hendriks
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2020
Current Panorama and Challenges for Neoadjuvant Cancer ImmunotherapyJose Carlos Benitez, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2021
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLCDipesh Uprety, Jordi Remon, Alex A Adjei
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2019
Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?Jordi Remon, Lizza Hendriks, Sandrine Aspeslagh, et al.
Clinical Lung Cancer|July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 ExpressionLizza E L Hendriks, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Pageof 19

Showing results (31-40 of 184) with videos related to

Sort By:
Pageof 19
BMC Medicine|April 22, 2017
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Jordi Remon, Benjamin Besse, Jean-Charles Soria
Translational Lung Cancer Research|February 11, 2020
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Frontiers in Oncology|April 1, 2022
Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic MalignanciesGiulia Pasello, Jordi Remon, Emanuela Felley-Bosco
Future Oncology (London, England)|May 16, 2020
Combination treatments with immunotherapy in brain metastases patientsClemence Henon, Jordi Remon, Lizza El Hendriks
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2020
Current Panorama and Challenges for Neoadjuvant Cancer ImmunotherapyJose Carlos Benitez, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2021
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLCDipesh Uprety, Jordi Remon, Alex A Adjei
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2019
Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?Jordi Remon, Lizza Hendriks, Sandrine Aspeslagh, et al.
Clinical Lung Cancer|July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 ExpressionLizza E L Hendriks, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Pageof 19